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Introduction
Thyroid cancer is the most common endocrine malignancy and accounts for most cancers of the endocrine system. It has a frequency that is higher in women (approximately 3: 1 ratio), which means an increased incidence rate by gender. Some investigators have suggested that the higher occurrence rate in women may be due to hormonal, reproductive, dietary, and molecular factors, the last of which are unknown [1] . In Brazil, the estimated incidence rate of thyroid cancer evaluated by the Brazilian National Cancer Institute (INCA) [2] was 7.91 cases per 100,000 females. In males, however, due to the low incidence, no calculation was performed. In the United States, 62,980 new cases were expected in 2014, with 47,790 of them in females [3] .
There are two types of endocrine thyroid cells from which thyroid cancers are derived: follicular thyroid cells and parafollicular C cells [4] . Medullary thyroid cancers that are parafollicular thyroid C cells in origin have been observed in about 5% of all thyroid cancers [1] . Follicular thyroid cell-derived tumors include papillary thyroid cancer (PTC), follicular thyroid cancer, and anaplastic thyroid cancer [5] [6] [7] [8] [9] . PTC and follicular thyroid cancer are collectively classified as well-differentiated thyroid cancers and account for around 95% of thyroid malignancies. Although the majority of papillary and follicular thyroid carcinomas are sporadic, familial tumors may account for 5-10% of thyroid carcinoma cases [1, 10] .
Recent progress in the understanding of the molecular pathogenesis of thyroid cancer has stemmed from the identification of molecular alterations, including the genetic and epigenetic alterations of signaling pathways, such as the RAS-RAF-MEK-MAPK-ERK pathway (MAPK pathway) and the PI3K-AKT pathway. The identification of these alterations in different signaling pathways has led to the development of more effective treatment strategies that target these particular signaling perturbations [8, 11] .
Mutations in genes coding for the different subunits of succinate dehydrogenase (SDHx) have also been associated with the development of thyroid cancer [12, 13] . SDH or complex II is a heterotetrameric protein composed of two hydrophilic catalytic subunits (SDHA and SDHB) and two hydrophobic subunits (SDHC and SDHD) anchored to the mitochondrial membrane [14, 15] . SDH is situated at the intersection of the tricarboxylic acid cycle and mitochondrial oxidative phosphorylation. Hence, SDH is at the center of the two essential energy-producing processes of the cell, and its dysfunction due to genetic alterations may lead to tumor formation through a complex mechanism involving hypoxia-signaling abnormalities [16] [17] [18] .
Mutations or loss of heterozygosity of the genes SDHA, SDHB, SDHC, and SDHD have been described in paragangliomas, pheochromocytomas [19] [20] [21] [22] , renal cell carcinoma [19, 23, 24] , gastrointestinal carcinoma [19] , familial pheochromocytoma and paraganglioma [14, [24] [25] [26] [27] ] , Cowden's syndrome [22, 23] , medullar [1, 19] and papillary thyroid carcinoma [14, 19, 24] , and more recently pituitary adenomas [28] [29] [30] .
In the course of this study, we investigated the SDHA , SDHB , SDHC and SDHD genes in a large Brazilian family, several members of whom presented with PTC.
Materials and Methods

DNA Collection
The sampling of epithelial buccal cells was performed as previously described [31] . After the collection 10 μl of proteinase K (20 mg/ml) were added to the solution, being left overnight at 65 ° C, DNA was purified by adding ammonium acetate 10 M , precipitated with isopropanol and resuspended with 50 μl of Tris 10 m M (pH 7.6) and EDTA 1 m M .
Polymerase Chain Reaction-Single-Stranded Conformational Polymorphism
To examine the association of the SDH genes with familiar thyroid papillary carcinoma, the coding regions of SDHA (NM_ 004168 -15 exons), SDHB (NM_003000 -8 exons), SDHC (NM_ 003001 -6 exons) and SDHD (NM_003002 -4 exons) were analyzed.
Polymerase chain reaction (PCR)-single-stranded conformational polymorphism (SSCP) and direct sequencing were used for the study. For the PCR-SSCP, 25 μl of final reaction volume were used. The analysis of all samples was performed as previously described [31] using the primers and conditions described in online supplementary table 1 (for all online suppl. material, see www. karger.com/doi/10.1159/000444522).
Direct Sequencing
To characterize the SSCP common pattern, DNA samples from 2 healthy individuals, 35 and 50 years of age, were used as technical controls. None of them had any reports of developing cancer in their families to date of collection. Two samples of each exon were sequenced in the case no different pattern was found by SSCP and all samples were sequenced to confirm the mutation segregation pattern every time a mutation was found. The PCR product was amplified using BigDye ® Terminator V3.1 (Life Technologies, Grand Island, N.Y., USA) purified using the ZR DNA Sequencing Clean-Up Kit TM (Zymo Research, Irvine, Calif., USA) and analyzed by classical bidirectional Sanger sequencing. Case II-9. A 62-year-old female presented with multinodular goiter. Thyroid ultrasound (US) showed an enlarged multinodular thyroid gland (thyroid volume was 76.89 cm 3 , normal range for females: 10-12 ± 2 cm 3 ), with a predominant nodule measuring 2.0 cm in its largest diameter. Thyroid function tests showed that thyrotropin (TSH) and free thyroxine hormone levels (fT 4 ) were within the normal range: 0.5 μUI/ml (normal range: 0.35-5.00 μUI/ml) and 0.9 ng/dl (normal range: 0.7-1.8 ng/dl), respectively. US-guided fine-needle aspiration (FNAC) of the largest nodule revealed a PTC. Total thyroidectomy (with lymph node ablation due to an enlarged nodule) was performed and histological analysis confirmed the presence of PTC. Unfortunately, the information regarding histological subtype, multifocality, and involvement of the lymph nodes that were removed was not available since this case was operated more than 20 years ago and not all the medical records were available.
Case II-10: A 65-year-old female presented with a 4-cm mass and tenderness in the upper left abdominal quadrant. An upper-gastrointestinal barium study and gastric endoscopic examination revealed a submucosal tumor, without obvious ulceration, in the upper part of the stomach. Endoscopic ultrasonogram showed an approximately 4-cm hypoechoic lesion with a hyperechoic area. An endoscopic biopsy was performed and confirmed GIST.
Case III-9. A 45-year-old male presented with a solitary solid thyroid nodule, immobile in palpation, measuring 1.5 × 0.8 cm. US-guided FNAC revealed a PTC. Total thyroidectomy was performed and the histological analysis confirmed the diagnosis of PTC. Information regarding histological subtype was not available as in case III-9.
Case III-11. A 44-year-old female presented with multinodular goiter (thyroid gland volume: 65.3 cm 3 ), with a predominant nodule measuring 3.8 cm in its largest diameter. Thyroid function tests were within the normal range (TSH: 1.9 μUI/ml, fT 4 3 ) and bilateral hypoechoic nodules with a predominant nodule measuring 1.6 cm in its largest diameter. US-guided FNAC of this nodule revealed a PTC. Thyroid function tests were normal (TSH: 3.22 μUI/ml). A total thyroidectomy was performed and histological analysis confirmed the presence of a conventional PTC in the predominant nodule.
Case III-23. A 29-year-old female was diagnosed with multinodular goiter. US-guided FNAC of one of the nodules revealed a PTC. Thyroid function tests were within the normal range (TSH: 4.47 μUI/ml; fT 4 : 1.5 ng/dl). A total thyroidectomy was performed and histological analysis confirmed the diagnosis of a conventional PTC.
Genetic Analysis
No novel or previously reported genetic variants in the genes SDHB , SDHC , and SDHD were detected. One missense mutation on SDHA (NM_004168 -OMIM: 600857) c.1919A>G (p.E640G/rs372480044) was found, but it did not segregate with the disease since it was found in 2 affected members (III-11, who had PTC and GIST, and III-23) and in 3 unaffected individuals (III-21, IV-31, and IV-33). This mutation is rare (not found in the 1000 Genomes Project), although it is predicted to be nonpathogenic by in silico prediction using the PolyPhen2 analysis tool (http://genetics.bwh.harvard.edu/pph/). All available family members and all patients were screened (completely sequenced) and no disease segregating mutations were found for the genes BRAF , JUNB , CDKN1B, or PTEN (data not shown).
Discussion
SDHx variants can be associated with PTC [13] . In addition, approximately 12% of the wild-type GIST without personal or family history of paraganglioma have germline mutations in SDHB or SDHC [32] . We described a large Brazilian family that presents with PTC and/or GISTs, but no SDHx mutations were detected except for a rare genetic variant, which was shown to be nonpathogenic by in silico analysis. Although the SDH-related tumor spectrum has been recently expanded, there are only a few reports of nonpheochromocytoma/paraganglioma tumors in SDHx -mutated patients [14, [31] [32] [33] [34] [35] [36] . In particular, 1-5% of SDHB / SDHD mutation carriers with paragangliomas/pheochromocytomas were found to present renal cells or PTC [14] . The association of germline mutations of the succinate dehydrogenase subunit genes and thyroid cancer are reported in table 1 . Neumann et al. [13] was the first to report the possible association of SDHx mutations with thyroid cancer. Other studies [14, 24] have shown that germline variants of the S DHB , SDHC, or SDHD genes may occur in a subset of PTEN mutation-negative Cowden and Cowden-like syndrome individuals. These individuals presented more frequently with breast, thyroid, and renal cancers beyond those conferred by germline PTEN mutations [14] . In the absence of PTEN alteration, Cowden or Cowden-like syndrome-related SDHx variants show increased phosphorylation of AKT and/or MAPK [14] . The proposed molecular mechanism of carcinogenesis in cases presenting with SDH x variants was based on the disruption of the complex II leading to mitochondrial metabolite imbalance, HIF1α accumulation, and ROS generation [23, 24] . SDH loss causes succinate accumulation and activation of pseudohypoxia signaling via overexpression of HIF proteins. Activation of insulin-like growth factor 1-signaling is also typical of these tumors. SDH-deficient GISTs are a unique group of GISTs with an energy metabolism defect as the key oncogenic mechanism [37] .
Our family included 4 cases with PTC, 1 case with coexistence of PTC and GIST, and 1 case with GIST alone. The coexistence of bilateral pheochromocytomas, abdominal paraganglioma, papillary thyroid carcinoma, and parathyroid adenoma has already been described in the literature [38] [39] [40] . GIST and thyroid cancer coexisted in 2.5% of the cases [38] . In our cases, sporadic coincidence of the described tumors is highly unlikely considering that 5 out of 13 family members presented with PTC. Recently, the Slit-Robo Rho GTPase activating protein 1 gene (SRGAP1) was identified as a candidate gene in PTC susceptibility in families with nonmedullary thyroid cancer using linkage analysis and association studies [41] . The authors speculate that 2 missense variants in SR-GAP1 (p.Q149H and p.R617C) could be loss-of-function-type changes affecting CDC42 activity; the latter has a well-defined function in cell proliferation, survival, and migration. Although SRGAP1 is a low-penetrant susceptibility gene in PTC, screening for genetic variations of this gene is warranted [41] .
No genetic alterations were identified in another study with sporadic PTC which analyzed the association between SDHB and SDHC genes, but very significant reductions in the SDHC expression were. By analyzing the expression of the SDHx gene in differentiated carcinoma samples, a classic PTC histology was overrepresented among patients with low overall SDHx expression compared with those with other histologic types, especially the follicular variant form of PTC [42] .
In this article we report a large pedigree with familial PTC associated also with other thyroid disorders and/or GISTs in which we were not able to identify genetic variations in the genes SDHA, SDHB, SDHC, and SDHD (mutations in the genes BRAF , JUNB, CDKN1B, and PTEN had already been excluded). Although the family is large and presents a variety of thyroid diseases showing great significance for research, it is interesting to note that 25% of consanguineous individuals were unavailable for genetic analysis and relevant information, which was a limitation of our study. These data suggest the likely presence of a different molecular pathway that should be investigated. Further genetic analysis, including next-generation sequencing studies is needed to identify new genes and understand the carcinogenic process leading to thyroid carcinoma formation.
